CONMED

Global Aging And Minimally Invasive Trends Will Empower Future Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

05 May 25

Updated

23 Jul 25

AnalystHighTarget's Fair Value

US$80.00

30.2% undervalued

23 Jul

US$55.81

-22.4%

5.1%

Author's Valuation

US$80.0

30.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25

AnalystHighTarget Fair Value

US$80.0

30.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.55%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.68%

Calculation

US$155.90m

Earnings '28

20.22x

PE Ratio '28

US$3.15b

Market Cap '28

US$3.15b

Market Cap '28

31.27m

No. shares '28

US$100.80

Share Price '28

US$100.80 Share Price '28

Discounted to 2025 @ 8.32% p.a.

US$79.30

Fair Value '25